TrialSafety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721
Trial details
- Registry ID
- NCT02682407
- Phase
- Phase 2
Drug research
OMS721 (narsoplimab)
Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.
Drug identity checked against registry records
Also recorded as narsoplimab
A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.
Included trials
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721NCT02682407 | Omeros Corporation | Phase 2 | Terminated | 2020-08-25Actual |
| Safety and Efficacy Study of OMS721 in Patients With Atypical Hemolytic Uremic SyndromeNCT03205995 | Omeros Corporation | Phase 3 | Terminated | 2021-02-02Actual |
Safety and Efficacy Study of OMS721 in Patients With Atypical Hemolytic Uremic Syndrome
Trial details
- Registry ID
- NCT03205995
- Phase
- Phase 3
Regulatory dates and decisions
| No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed. |